Target intelligence / Profile preview

Gamma-crystallin D (CRYGD)

Target
CRYGD
Molecular classification
Structural protein, Crystallin family (gamma-crystallin subgroup)
01

Overview

Gamma-crystallin D (CRYGD) is a highly stable, monomeric structural protein predominantly found in the vertebrate eye lens. It belongs to the gamma-crystallin family, which is part of the larger ubiquitously expressed crystallin superfamily involved in maintaining lens transparency and optimal refractive properties. Unlike most proteins, gamma-crystallins are synthesized during lens development and then retained without turnover for the organism’s lifetime due to the anucleate state of mature lens fiber cells. Mutations, post-translational modifications (such as deamidation), or age-related changes in CRYGD can induce aggregation, resulting in lens clouding and cataract formation. Though not a classical drug target (such as an enzyme, transporter, or receptor), CRYGD's stability and aggregation propensity are central to cataract pathogenesis, making it of major interest in lens biology and disease research

Other names
Gamma-crystallin DCRYGDCRYG4Gamma-D-crystallinGamma-crystallin 4CACACCA3CCPCTRCT4PCCcry-g-Dgamma-crystallin 4gamma-D-crystallin
02

Biological functions

Maintenance of eye lens transparencyMaintenance of refractive index in the lensStructural constituent of the eye lens
03

Disease associations

Cataract (especially congenital and age-related forms)
04

Safety considerations

Aggregation/misfolding may cause lens opacity and contribute to cataract formationLong-term retention may increase susceptibility to age- or mutation-induced aggregation
05

Biomarkers

Potential biomarker for cataractogenesis or eye lens opacity

Beyond the preview

Go deeper on Gamma-crystallin D (CRYGD).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gamma-crystallin D (CRYGD).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call